Vaccine hesitancy and emergence of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants of concern (VOCs) escaping vaccine-induced immune responses …

The SARS-CoV-2 variants replacing the first wave strain pose an increased threat by their
potential ability to escape pre-existing humoral protection. An angiotensin converting …

Soluble angiotensin-converting enzyme 2 (ACE2) constitutes an attractive antiviral capable
of targeting a wide range of coronaviruses using ACE2 as their receptor. Using structure …

Monoclonal antibodies targeting the SARS‐CoV‐2 spike (S) neutralize infection and are
efficacious for the treatment of COVID‐19. However, SARS‐CoV‐2 variants, notably …

As severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) evolves to escape
natural antibodies, it also loses sensitivity to therapeutic antibody drugs. By contrast …

Many of the currently available COVID-19 vaccines and therapeutics are not effective
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …

The human angiotensin-converting enzyme 2 acts as the host cell receptor for SARS-CoV-2
and the other members of the Coronaviridae family SARS-CoV-1 and HCoV-NL63. Here, we …

Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in a severe global pandemic. Following …

Infection and viral entry of SARS-CoV-2 crucially depends on the binding of its Spike protein
to angiotensin converting enzyme 2 (ACE2) presented on host cells. Glycosylation of both …

The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus
preventional or therapeutical strategies highly sought after. Here we report a human …